Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Benralizumab is an IL-5Rα-directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma.

Related collections

Author and article information

Journal

Title: The Journal of Allergy and Clinical Immunology: In Practice

Abbreviated Title: The Journal of Allergy and Clinical Immunology: In Practice

Publisher: Elsevier BV

ISSN (Print): 22132198

Publication date Created: December 2021

Publication date (Print): December 2021

Volume: 9

Issue: 12

Pages: 4381-4392.e4

Article

DOI: 10.1016/j.jaip.2021.07.058

PubMed ID: 34487870

SO-VID: 0bc1e4f4-333e-414b-a89a-d7b7c43421a0

License:

https://www.elsevier.com/tdm/userlicense/1.0/

http://creativecommons.org/licenses/by/4.0/

History

Data availability:

Comments

Comment on this article

scite_

Cited by 29

See all cited by

- Version 1